News headlines about Xenetic Biosciences (NASDAQ:XBIO) have trended positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Xenetic Biosciences earned a media sentiment score of 0.33 on Accern’s scale. Accern also assigned headlines about the company an impact score of 48.7903648847072 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Separately, Zacks Investment Research upgraded Xenetic Biosciences from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Saturday, September 9th.
Xenetic Biosciences (NASDAQ XBIO) opened at $1.92 on Friday. Xenetic Biosciences has a 12-month low of $1.75 and a 12-month high of $5.90. The company has a market cap of $17.09, a PE ratio of -1.55 and a beta of 2.20.
About Xenetic Biosciences
Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.
What are top analysts saying about Xenetic Biosciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Xenetic Biosciences and related companies.